Benefits of Standardized Chronic Disease Management Programs on Comorbidity and Mortality in a Population-based Cohort in China

Presenter Di, Qian 底骞

Vanke School of Public Health, Tsinghua University, China

qiandi@tsinghua.edu.cn

27/09/2024

VORLD CONGRESS OF EPIDEMIOLOGY 2024

What are the health benefits of basic public health service?

- In many countries, basic public health services are provided to residents
 - U.S.: 10 essential public health services
 - China: 12 basic public health services, including hypertension and type 2 diabetes management, healthcare for elder people, pregnant women...
 - In China, government pays 89 yuan (12.4 dollars/11.6 euros) per person per year.
- What are the health benefits of providing public health

services?

The Futures Initiative: the 10 Essential Public Health Services Aligning the 10 Essential Public Health Services and the Foundational Public Health Services Sentember 2020


field for the field and describe core elements of public health practice. There is significant alignment between the two as outlined in the following tables and the relevant components of each foundational capability and area (which may relate to more than one Essential Service) are included and aligned with the corresponding EPHS. Table 1 provides an overview of alignment at the statement level and Table 2 provides more details on the components of each foundational capability and area.

ES Revised EPHS		Foundational Capability	Foundational Area	
1	Assess and monitor population health status, factors that influence health, and community needs and assets	 Assessment/Surveillance Emergency Preparedness and Response 	Chronic Disease and Injury Prevention Communicable Disease Control Environmental Public Health Maternal, Child, and Family Health	
2	Investigate, diagnose, and address health problems and hazards affecting the population	 Assessment/Surveillance Emergency Preparedness and Response 	Chronic Disease and Injury Prevention Communicable Disease Control Environmental Public Health Maternal, Child, and Family Health	
3	Communicate effectively to inform and educate people about health, factors that influence it, and how to improve it	 Communications Emergency Preparedness and Response 	Chronic Disease and Injury Prevention Communicable Disease Control Environmental Public Health Maternal, Child, and Family Health	
4	Strengthen, support, and mobilize communities and partnerships to improve health	 Community Partnership Development 	Chronic Disease and Injury Prevention Communicable Disease Control Environmental Public Health Maternal, Child, and Family Health	
5	Create, champion, and implement policies, plans, and laws that impact health	 Policy Development and Support 	Chronic Disease and Injury Prevention Communicable Disease Control Environmental Public Health Maternal, Child, and Family Health	

目 录

居民健康档案管理服务规范	. 1
健康教育服务规范	22
预防接种服务规范	26
0~6岁儿童健康管理服务规范	30
孕产妇健康管理服务规范	43
老年人健康管理服务规范	53
高血压患者健康管理服务规范	56
2 型糖尿病患者健康管理服务规范	61
严重精神障碍患者管理服务规范	66
肺结核患者健康管理服务规范	73
中医药健康管理服务规范	81
传染病及突发公共卫生事件报告和处理服务规范	92
卫生计生监督协管服务规范	95

Overall Framework and Descriptive Statistics of the Shenzhen Cohort




- Confirming the baseline through Integrating community health center data and hospital data
- Obtaining follow-up records of the population under Hypertension and Type 2 Diabetes Management Programs
- Ascertaining outcomes through medical diagnosis data

Topic: Can Hypertension and Type 2 Diabetes Management policies reduce the risk for comorbidity and mortality?

Population: Newly diagnosed hypertension (total 701,759 subjects, 231,352 included in management) and type 2 diabetes (total 320,179 subjects, 105,593 included in management) patients from 2018 to 2023.

Outcome: Mortality / comorbidity risk with new chronic diseases.



Topic: Can Hypertension and Type 2 Diabetes Management policies reduce the risk for comorbidity and mortality?

Population: Newly diagnosed hypertension (total 701,759 subjects, 231,352 included in management) and type 2 diabetes (total 320,179 subjects, 105,593 included in management) patients from 2018 to 2023.

Outcome: Mortality / comorbidity risk with new chronic diseases.

Result: Both Hypertension and Type 2 Diabetes Health Management Program can significantly reduce mortality from all causes and specific causes.

Enrolled in the Hypertension and Type 2 Diabetes Health Management Program lowered the risk of death from all causes by 20% (HR, 0.80; 95% CI, 0.75-0.85) and 27% (95% CI, 0.68-0.79), respectively.

We also found significant associations between the enrollment and declined mortality from cardiovascular diseases, and diabetes and kidney diseases.

A. Type 2 Diabetes

	<i>P</i> value
All causes	<.001
Cardiovascular diseases	<.001
Ischemic heart disease	<.001
Stroke	<.001
Hypertensive heart disease	.10
Diabetes and kidney diseases	<.001
Diabetes mellitus	<.001
Chronic kidney disease	<.001

Deselves

B. Hypertension

		<i>P</i> value
All causes	•	<.001
Cardiovascular diseases	-	<.001
Ischemic heart disease	HEH	<.001
Stroke	H B -1	<.001
Hypertensive heart disease	⊢−−− ■	<.01
Diabetes and kidney diseases		<.01
Diabetes mellitus	⊢−− ■−−•	.07
Chronic kidney disease	⊢ ∎→	<.001

Topic: Can Hypertension and Type 2 Diabetes Management policies reduce the risk for comorbidity and mortality?

Population: Newly diagnosed hypertension (total 701,759 subjects, 231,352 included in management) and type 2 diabetes (total 320,179 subjects, 105,593 included in management) patients from 2018 to 2023.

Outcome: Mortality / comorbidity risk with new chronic diseases.

Result: Both Hypertension and Type 2 Diabetes Health Management Program can significantly reduce incidence of ^{Other cardiovascular and circula} comorbidity with other new diseases.

Among 84 chronic disease outcome we identified, Hypertension Management reduced comorbidity risk of 28 diseases and Type 2 Diabetes Management reduced comorbidity risk of 25 diseases.

		Hypertension		Diabetes	
	Population	HR (95% CI) HR (95% CI)			
	All population				
	Comorbidity with one new disease	0.95 (0.94-0.96) ***	•	0.94 (0.93-0.95) ***	•
9	Comorbidity with two new diseases	0.94 (0.93-0.96) ***	•	0.93 (0.91-0.95) ***	+
	Comorbidity with three new diseases	0.95 (0.94-0.97) ***	+	0.92 (0.89-0.94) ***	+
	Comorbidity with four new diseases	0.95 (0.93-0.97) ***	+	0.91 (0.88-0.94) ***	-
	Comorbidity with five new diseases	0.94 (0.91-0.97) ***	-	0.92 (0.88-0.96) ***	 ¦

	Hypertension		Diabetes	
Cardiovascular and cerebrovascular diseases -	•	***	•	***
Ischemic heart disease 🗕	•	***	•	***
Rheumatic heart disease 🗕	i	**	i	
Stroke -	•	***	+	***
Cardiomyopathy and myocarditis				
Atrial fibrillation and flutter	•	***		
Hypertensive heart disease	+	***		***
Other cardiovascular and circulatory diseases	_ 		_ _	
Respiratory diseases – Chronic obstructive pulmonary disease – Asthma – Interstitial lung disease and pulmonary sarcoidosis – Other chronic respiratory diseases –	* * *	 	+ + + +	
Mental disorders -	* 1	***		***
Depressive disorders -		***		
Anxiety disorders		***		
Schizophrenia -				
Mania -		→		
Bipolar disorder				
Conduct disorder		***		
Eating disorders – Other mental disorders –				


Topic: Can hypertension and diabetes management policies reduce the risk for multiple chronic diseases?

Population: Newly diagnosed hypertension (total 702,913 subjects, 231,340 included in management) and diabetes (total 325,117 subjects, 105,591 included in management) patients from 2018 to 2023.

Outcome: Mortality / comorbidity risk with new chronic diseases.

Result: Both hypertension and diabetes health management program can significantly reduce comorbidity risk with other new chronic diseases.


Hypertensive patients with well-controlled blood pressure and type 2 diabetic patients with well-controlled fasting blood glucose benefited more from the management.



Topic: Can specific interventions in Hypertension and Type 2 Diabetes Management reduce the risk for comorbidity and mortality?

Population: Newly diagnosed hypertension (total 701,759 subjects, 231,352 included in management) and type 2 diabetes (total 320,179 subjects, 105,593 included in management) patients from 2018 to 2023.

Outcome: Mortality / comorbidity risk with other new diseases.




Topic: Can specific interventions in Hypertension and Type 2 Diabetes Management reduce the risk for comorbidity and mortality?

Population: Newly diagnosed hypertension (total 701,759 subjects, 231,352 included in management) and type 2 diabetes (total 320,179 subjects, 105,593 included in management) patients from 2018 to 2023.

Outcome: Mortality / comorbidity risk with other new diseases.

Result: With increasing number of interventions with target achieved, we found stepwise reductions of mortality from all causes in a dose-response manner among type 2 diabetic and hypertensive enrollees, compared to non-enrollees.

For type 2 diabetic patients, three or more interventions with target achieved were required to significantly reduce mortality; while for hypertension, five or more were needed.



Management
 Type 2 Diabetes
 Hypertension

Topic: Can specific interventions in Hypertension and Type 2 Diabetes Management reduce the risk for comorbidity and mortality?

Population: Newly diagnosed hypertension (total 701,759 subjects, 231,352 included in management) and type 2 diabetes (total 320,179 subjects, 105,593 included in management) patients from 2018 to 2023.

Outcome: Mortality / comorbidity risk with other new diseases.

Result:

Physical activity intervention with target achieved lowered the risk of death from all causes (HR, 0.53; 95% Cl, 0.44-0.63) among type 2 diabetic patients, and death from all causes (HR, 0.70; 95% Cl, 0.60-0.82) among hypertensive patients.

Smoking intervention with target achieved significantly reduced the risk of all-cause mortality (HR, 0.74; 95% CI, 0.59-0.91) among type 2 diabetic patients.

			HR (95% CI)
Smoking intervention		1	
Type 2 Diabetes	—		0.74 (0.59–0.91
Hypertension			0.99 (0.81–1.23
Drinking Intervention			
Type 2 Diabetes			1.14 (0.90–1.44
Hypertension		· · · · · · · · · · · · · · · · · · ·	1.29 (1.03–1.62
Physical activity interven	tion	1	
Type 2 Diabetes			0.53 (0.44–0.63
Hypertension	⊷		0.70 (0.60–0.82
Diet intervention		1	
Type 2 Diabetes		⊢	1.42 (1.21–1.67
Hypertension			1.04 (0.90–1.20
Medication intervention			
Type 2 Diabetes	F		0.88 (0.72–1.06
Hypertension	H	—	0.77 (0.65–0.91
Psychology intervention			
Type 2 Diabetes		⊢	1.06 (0.81–1.38
Hypertension	—	•	0.83 (0.65–1.07
Adherence intervention			
Type 2 Diabetes	⊢		0.87 (0.67–1.13
Hypertension		—	1.03 (0.81–1.32
	0.4	4	


Topic: Can specific interventions in Hypertension and Ty 2 Diabetes Management reduce the risk for comorbidity mortality?

Population: Newly diagnosed hypertension (total 701,7 subjects, 231,352 included in management) and type 2 diabetes (total 320,179 subjects, 105,593 included in management) patients from 2018 to 2023.

Outcome: Mortality / comorbidity risk with other new diseases.

Result:

Smoking intervention reduced the comorbidity risk of cardiovascular and cerebrovascular diseases, while increasing risks of other diseases among hypertensive patients. Drinking intervention, medication adherence intervention and psychology intervention showed comprehensive health effects for both hypertensive and type 2 diabetic patients.




Hypertensive patients

Diabetic patients

p < 0.05 p = 0.05

Comparing Platform to Academic





Acknowledgements

Support from the National Natural Science Foundation of China Qian Di lab, Tsinghua University







Key messages

- Standardized chronic disease management program can significantly reduce all-cause mortality, cause-specific mortality, and incidences of comorbidity with other new diseases
- Well-controlled patients have better health outcomes than people who do not
- Patients who completed more lifestyle interventions had greater mortality reductions
- Empirical evidence for basic public health service
- Open platform to all researchers in the future

Thank you for listening

Presenter Di, Qian 底骞

Vanke School of Public Health, Tsinghua University, China qiandi@tsinghua.edu.cn

27/09/2024

